65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 10 of 500 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05754450 (ClinicalTrials.gov)	April 21, 2023	6/2/2023	An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion ...	A Phase 3, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of AVTX-803 in Su ...	Leukocyte Adhesion Deficiency	Drug: AVTX-803	Avalo Therapeutics, Inc.	NULL	Not yet recruiting	6 Months	75 Years	All	2	Phase 3	United States
2	NCT05193552 (ClinicalTrials.gov)	April 1, 2023	6/8/2021	Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease	A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement D ...	Common Variable Immunodeficiency	Drug: Hizentra	University of Alabama at Birmingham	NULL	Not yet recruiting	21 Years	N/A	All	22	Phase 4	NULL
3	NCT05593588 (ClinicalTrials.gov)	March 1, 2023	21/10/2022	Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency	Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency(CV ...	Common Variable Immunodeficiency;Interstitial Lung Disease Due to Systemic Disease	Drug: Fisetin;Drug: Placebo	Avni Joshi	NULL	Not yet recruiting	18 Years	N/A	All	20	Phase 2	United States
4	EUCTR2020-004734-37-HU (EUCTR)	24/01/2023	17/11/2022	Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Imm ...	Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, eff ...	Primary ImmunodeficiencyDiseases MedDRA version: 20.0;Level: PT;Classification code 10064859;Term: P ...	Product Name: Newnorm INN or Proposed INN: Newnorm Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN ...	Octapharma Pharmazeutika Prod.Ges.m.b.H	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 1;Phase 3	United States;Hungary;Slovakia;Poland;Ukraine;Germany;Netherlands;Italy
5	NCT05398809 (ClinicalTrials.gov)	January 18, 2023	26/5/2022	Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyend ...	A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Pa ...	Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced);Alopecia Areata	Drug: Ruxolitinib	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	12 Years	65 Years	All	70	Phase 2	United States
6	NCT05600907 (ClinicalTrials.gov)	January 2, 2023	26/10/2022	Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomato ...	Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granu ...	Chronic Granulomatous Disease;CGD	Biological: JSP191	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	4 Years	65 Years	All	30	Early Phase 1	United States
7	NCT05071222 (ClinicalTrials.gov)	January 2023	27/8/2021	Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Le ...	A Phase 1/2 Open Label Non Randomized Study, Multicentric, Single Arm Evaluating the Safety and Effi ...	Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency	Genetic: ARTEGENE drug product	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	N/A	1 Year	All	5	Phase 1/Phase 2	France
8	NCT05396105 (ClinicalTrials.gov)	December 28, 2022	28/4/2022	Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Heredi ...	A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema ...	Hereditary Angioedema;Hereditary Angioedema Type I;Hereditary Angioedema Type II;Hereditary Angioede ...	Drug: PHA-022121 low dose;Drug: PHA-022121 medium dose;Drug: PHA-022121 high dose;Drug: PHA-022121 s ...	Pharvaris Netherlands B.V.	NULL	Recruiting	18 Years	N/A	All	72	Phase 2/Phase 3	United States;Bulgaria;Czechia;France;Germany;Hungary;Spain
9	JPRN-jRCT2031210309	20/12/2022	13/09/2021	RALPID	Phase 2 study of the efficacy and safety of sirolumus in patients with primary immunodeficiency	Primary immunodeficiency PID, ALPS, APDS, CTLA4, IPEX, lymphoproliferative disease, enterocolitis, c ...	Administer sirolimustablets or granules once a daily. Initial dose: 2mg (tablet), 0.049 mg/kg or 0.03 ...	Endo Akifumi	NULL	Recruiting	>= 2month old	Not applicable	Both	10	Phase 2	Japan
10	EUCTR2021-001226-21-DE (EUCTR)	01/12/2022	08/03/2022	A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patie ...	A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the E ...	Hereditary Angioedema Type Ior II MedDRA version: 21.0;Level: LLT;Classification code 10080956;Term: ...	Product Name: KVD900 300 mg Film Coated Tablet INN or Proposed INN: sebetralstat Other descriptive name ...	KalVista Pharmaceuticals Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	114	Phase 3	Portugal;United States;Slovakia;Greece;Spain;North Macedonia;Israel;United Kingdom;Italy;France;Hung ...

First Previous1 2 3 4 5…50Next Last